Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access of MK-3475 in Metastatic Melanoma Patients With Limited to No Treatment Options

Trial Profile

Expanded Access of MK-3475 in Metastatic Melanoma Patients With Limited to No Treatment Options

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Malignant melanoma; Uveal melanoma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Acronyms KEYNOTE-030
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Mar 2017 Results (n=315) of KEYNOTE-001,KEYNOTE-002, KEYNOTE-006 and one expanded acces phase II study assessing clinicopathological factors in PD-1 antibodies response published in the British Journal of Cancer.
    • 15 Nov 2016 Results of retrospective analysis from pooled data of this and other five studies (n=60) published in the Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top